Pharmafit Provence
AURIGOUTTE Ear drops Bottle/15ml

P&G Health France

AURIGOUTTE Ear drops Bottle/15ml

CIP / EAN code: 3400932296835

Product information from VIDAL.

Read the product information

Product information

Find indications, dosage and precautions in the sections below.

Automatic English translation of the French VIDAL document. Original numerical values and units are retained, including decimal commas.

VIDAL
Medicines
SmPC of 17/02/2020

AURIGOUTTE, auricular drops


Forms and presentations

Auricular drops.


Composition

Hexamidine diisethionate ..........................................................................................................0,100 g

Lidocaine hydrochloride ........................................................................................................... 0,100 g

For 100 ml.


Excipients:

Officinal glycerol, ethyl alcohol at 95°.



Indications

Antiseptic treatment of external otitis with intact tympanic membrane and their painful manifestations.



Dosage and administration

Dosage

Adults: 4 drops 3 times a day.

Paediatric population

Infants and children: 2 drops 3 times a day.

Duration of treatment

5 days.



Contraindications

Hypersensitivity to the active substances or to any of the excipients listed in section Composition.



Warnings and precautions

It is imperative to have the state of the tympanic membrane checked before any use because of the risks of ear toxicity in case of tympanic membrane perforation.



Interactions

No interaction studies have been performed.



Fertility, pregnancy and breastfeeding

Pregnancy

There is no reliable data on teratogenesis in animals. In clinical practice, no particular malformative or foetotoxic effect has appeared to date. However, follow-up of exposed pregnancies is insufficient to exclude any risk.

Consequently, as a precautionary measure, it is preferable not to use this medicine during pregnancy.



Driving and using machines

The effects on the ability to drive vehicles and use machines have not been studied.



Adverse effects

Like any active product, this medicine may cause more or less troublesome effects in some people.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system: National Agency for the Safety of Medicines and Health Products (ANSM) and the network of Regional Pharmacovigilance Centres - Website:www.signalement-sante.gouv.fr.



Overdose

No cases of overdose have been reported.



Pharmacodynamics

Pharmacotherapeutic class: otological medicines, ATC code: S02DA01.

Preparation for auricular use combining a local antiseptic of the diamidine family (hexamidine diisethionate) and a local anaesthetic (lidocaine hydrochloride).



Shelf life

2 years.



Special storage precautions

To be stored at a temperature not exceeding 30°C.



Prescription, supply and reimbursement

Marketing authorisation (AMM)
CIP 3400932296835 (Fl/15ml).
Not reimbursed by Social Security.

P&G Health France
163-165 QUAI AULAGNIER
92600 ASNIERES-SUR-SEINE CEDEX
Tél : 01 40 88 50 00 https://fr.pg.com/

Source: VIDAL · Updated on 10/11/2026. This information does not replace advice from a healthcare professional.